Essai Clinique

Généré le 29 mars 2024 à partir de

Titre	Étude de phase III: Radiothérapie par modulation d'intensité préopératoire VS post-opératoire pour les sarcomes des tissus mous du tronc et des extrémités.
Protocole ID	RxTx 50/50
ClinicalTrials.gov ID	n.d.
Type(s) de cancer	Sarcome
Phase	Phase III
Type étude	Traitement
Institution	CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX 5415 boul. de l'Assomption, Montréal, QC, H1T2M4
Ville	Montréal
Investigateur principal	Dr Nader Khaouam
Coordonnateur	Jany Barry 514-252-3400
Statut	Actif en recrutement
But étude	
Critères d'éligibilité	• Histologically proven soft tissue sarcoma of the extremity or trunk following review by local reference pathologist. • Deemed appropriate for preoperative or postoperative radiotherapy and conservative surgery following patient assessment by a radiation oncologist and surgical oncologist. • Lesion is primary or locally recurrent. Patient may have undergone excisional biopsy with positive margins at a referring hospital and are eligible following discussion among the surgical oncologists and radiation oncologists that IMRT is an acceptable treatment for that case. • ECOG 0-3 • Patient is aged 18 years or older. • Patient is able to provide informed consent • Patient is available for treatment and follow-up.
Critères d'exclusion	• Benign histology. • Prior malignancy within the previous five years or concurrent malignancy with the exception of adequately treated basal cell carcinoma of the skin or carcinoma in-situ of the cervix. • Prior radiotherapy to the target site • Planned chemotherapy for (neo)adjuvant treatment • Conservative surgery to the target site only • Presence of regional nodal disease or unequivocal distant metastases. • Other major medical illness deemed to preclude safe administration of protocol treatment or required follow-up.